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Abstract 
Alcohol use disorders (AUDs) cause serious problems in society and few 
effective treatments are available. Caenorhabditis elegans (C. elegans) is an excellent 
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invertebrate model to study the neurobiological basis of human behavior with a 
conserved, fully tractable genome, and a short generation time for fast generation of 
data at a fraction of the cost of other organisms. C. elegans demonstrate movement 
toward, and concentration-dependent self-exposure to various psychoactive drugs. The 
discovery of opioid receptors in C. elegans provided the impetus to test the hypothesis 
that C. elegans may be used as a medications screen to identify new AUD treatments. 
We tested the effects of naltrexone, an opioid antagonist and effective treatment for 
AUDs, on EtOH preference in C. elegans. Six-well agar test plates were prepared with 
EtOH placed in a target zone on one side and water in the opposite target zone of each 
well.  Worms were treated with naltrexone before EtOH preference testing and then 
placed in the center of each well. Wild-type worms exhibited a concentration-dependent 
preference for 50, 70 and 95% EtOH. Naltrexone blocked acute EtOH preference, but 
had no effect on attraction to food or benzaldehyde in wild-type worms. Npr-17 opioid 
receptor knockout mutants did not display a preference for EtOH.  In contrast, npr-17 
opioid receptor rescue mutants exhibited significant EtOH preference behavior, which 
was attenuated by naltrexone. Chronic EtOH exposure induced treatment resistance 
and compulsive-like behavior. These data indicate that C. elegans can serve as a model 
system to identify compounds to treat AUDs.  
 
Keywords: alcohol, behavior, preference, reinforcement, nematode. 
 
 
 
1. Introduction 
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Addiction represents a major and growing challenge in our society. It takes a 
massive toll in both direct and indirect human and financial costs.  The resulting costs to 
society are approximately 740 billion dollars annually in the U.S. alone [1]. Clearly, there 
is an urgent need for effective treatments and prevention strategies developed from an 
understanding of the mechanisms underlying addictive behavior. Much of what we know 
about the neurobiology of addiction has been either discovered or enhanced through 
the use of animal models [2]. This includes the discovery and characterization of some 
of the basic reward circuitry and the development of behavioral measures to model and 
study human addiction in animals [3]. Development of pharmacotherapeutics is a 
promising avenue to reduce the impact of alcohol use disorders (AUDs); however, few 
effective treatments are currently available.  
Recent work has shown that addiction is a phylogenetically ancient process and 
indicates that many mechanisms that underlie addiction are present in invertebrates. 
Behavioral models of addiction, using alcohol self-administration, conditioned place 
preference (CPP), and other tools historically used to study aspects of addictive 
behavior in vertebrates [4], have also been developed for invertebrates. Crayfish show 
drug reward, seeking, and withdrawal to cocaine, amphetamines and opiates [5]. 
Similarly, ethanol (EtOH) self-administration and conditioning paradigms have 
demonstrated that drosophila melanogaster show conditioned preference responses to 
cues that had been previously paired with EtOH [6]. Although some might find it 
surprising that such simple animals can be used to model complex behaviors, 
behavioral models using invertebrates have played a central role in the discovery of the 
molecular mechanisms that underlie learning and memory [7].  
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The nematode Caenorhabditis elegans (C. elegans) is an excellent model 
organism with conserved neurobiological systems that is often used to model various 
disease states [8]. It provides the researcher with numerous molecular and genetic 
tools, including a fully sequenced genome, the availability of thousands of genetic 
mutants, and the ability to manipulate other genes and their expression through 
transgenic approaches and RNAi techniques. In addition, a relatively short life cycle and 
a 3-day generation time from egg to adult can lead to a dramatic increase in the pace of 
discovery at a fraction of the cost inherent when using higher level organisms. We have 
discovered that, like mammals and other invertebrates, C. elegans also develops a 
conditioned preference for cues after previous pairings with methamphetamine or 
cocaine that is dependent on dopamine neurotransmission [9, 10]. Together, these data 
indicate that invertebrates, specifically C. elegans, show behavioral responses to 
addictive drugs that are consistent with those of higher level organisms.  
Recent research has established that C. elegans display depressed locomotion 
and functional tolerance after exposure to EtOH that is mediated, in part, through the 
BK potassium channel which appears to subserve behavioral responses across multiple 
species including humans [11, 12]. Importantly, EtOH’s effects on locomotor activity of 
C. elegans occur when the internal tissue concentration of EtOH reaches levels that 
correspond to intoxicating blood alcohol levels in humans [13]. Moreover, chronic 
exposure to EtOH induces adaptive changes that can enhance EtOH preference and 
self-exposure [14]. These data indicate that C. elegans show a concentration-
dependent attraction to EtOH that results in EtOH self-exposure and significant tissue 
concentrations of EtOH; furthermore, EtOH preference is enhanced after chronic 
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exposure. Recently, researchers have discovered an opioid receptor system in C. 
elegans [15], therefore, we sought to examine the effect of naltrexone on EtOH 
preference in C. elegans.  
EtOH self-administration and seeking behavior in non-human vertebrates are 
well established models to study alcohol use disorders (AUDs) [16]. In recent years, 
attention has turned to the application of these models for use in medications 
development and the identification of novel targets to treat AUDs [17, 18]. However, the 
application of these models is limited in the area of medication screening due to the 
need for relatively large amounts of sometimes expensive and rare test compounds that 
may only be available in very small quantities. In addition, the costs of these 
experiments in terms of technician effort and animal per-diem are also significant. 
Finally, the pace of discovery in these labor-intensive drug studies can be months or 
longer depending on the protocol. A validated model that employs C. elegans to screen 
compounds would be a major advancement in the field and provide a much-needed tool 
to conduct drug screens quickly and economically with the potential of dramatically 
increasing the pace of medication discovery.  
Specifically, the purpose of the present studies was to employ a voluntary EtOH 
self-exposure chemotaxis assay to examine the effects of naltrexone and/or chronic 
EtOH exposure on the appetitive properties of EtOH in wild-type and opioid receptor 
mutant C. elegans. Overall, these studies represent a first step toward the development 
and validation of a pharmacological drug screening procedure to identify compounds 
that effectively and selectively reduce the EtOH preference response in C. elegans. This 
high-throughput C. elegans medications screening model can enable fast and accurate 
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generation of data. The successful implementation of such models could provide 
powerful and novel tools in the search for new pharmacological treatments for AUDs.  
 
2. MATERIALS AND METHODS 
2.1 Materials 
All reagents and assay materials were purchased from Sigma-Aldrich and Fisher 
Scientific, unless indicated otherwise. Fifty and 70 % (v/v) EtOH solutions were 
prepared with 95% (v/v) EtOH and water for EtOH preference testing. Vehicle (0.97 or 
1.94 mM HCl; salt equivalent of 10 and 20 mM naltrexone HCl, respectively), and 10 
and 20 mM naltrexone HCl (N-3136; FW 377.9; Sigma-Aldrich) were used to pretreat 
animals prior to testing. Vehicle (0.97 or 1.94 mM HCl) and naltrexone dosing solutions 
were adjusted to a pH of 7.2 to 7.4 with NaOH.  Benzaldehyde (#418099; 99.5%; 
Sigma-Aldrich; FW 106.12) was used to test for nonselective effects of naltrexone HCl. 
2-nonanone (99%; CAS 821-55-6; FW 142.24; Arcos Organics) was used to show that 
animals could move away from the drug target zone. All concentrations of drugs include 
the salt.   
2.2 Culture and Maintenance of Strains 
The N2 Bristol wild-type (WT) strain was used in all assays. The npr-17 KO 
mutants [DA2457 npr-17(tm3210) III] lack npr-17, which encodes a protein with 
sequence similarity to opioid receptors, while the npr-17 rescue mutants [DA2582 npr-
17 (tm3210) III], in which the npr-17 gene was rescued (Cheong et al 2015), were used 
in the acute EtOH preference, benzaldehyde and food assays.  The npr-17 KO and 
rescue mutant strains were obtained directly from Dr. Cheong [15]. 
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All animals were maintained at 22°C, and all general culturing techniques have 
been described previously by Nass and Hamza [19]. Worms were grown with E. coli 
strain NA22 as a food source on maintenance plates, produced by filling 60-mm petri 
dishes with 10-ml regular NGM agar (25g bactoagar, 20g bactopeptone, 3g NaCl, 1L 
H20, 1ml cholesterol (5mg/ml 95% ethanol), 1ml 1M CaCl2, 1ml 1M MgSO4, and 25ml 
of potassium phosphate buffer).  The potassium phosphate buffer contained 5g of 
K2HPO4 dibasic/anhydrous, 30g of KH2PO4 monobasic, and 500ml of H20, pH 
adjusted to 6.0 [20]. 
Adult worms were used for all experiments to control for any effects of different 
sensitivities and responses to drugs at varying developmental stages. Worms were age 
synchronized by lysing gravid adults with bleach and sodium hydroxide, allowing eggs 
to be released into solution and hatched in M9 buffer [20]. After 18 hours, hatched L1 
larvae were washed three times with water, plated, and maintained on NGM plates with 
NA22 E. coli bacterial lawns until reaching adulthood. Testing began approximately 72 
hr after plating the L1 larvae, when worms were adults. 
6-well Costar™ cell culture plates were used to determine drug preference 
(Fisher cat. no. 07-200-80). Clear templates were taped to the bottom of each 6-well 
plate to create two 1.2 cm diameter circular target zones within the 3.5 cm diameter of 
each well. Test plates were produced by filling each well of the plates with 3.8ml of NaCl 
free agar (17g bactoagar, 2.5g bactopeptone, 1L H20, 1ml 1M CaCl2, 1ml 1M MgSO4, 
and 25ml of potassium phosphate buffer). Cholesterol was not included in the salt-free 
agar in order to obtain clearer images of worms during testing. Chemotaxis assays are 
typically performed in single well 60 mm or 100 mm plates.  However, in the present 
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studies we sought to create higher throughput for testing by scaling down the standard 
experimental parameters used in 60 and 100 mm plates, in order to perform chemotaxis 
assays in 6 well plates containing 35 mm wells.   
2.3 Naltrexone Pretreatment 
[Insert Figure 1 here] 
Worms were washed off maintenance plates with 15 ml of water and transferred 
to 15 ml centrifuge tubes. Adults were allowed to settle on the bottom of each tube for 5 
min and then the supernatant was removed. This was repeated two more times with 10 
ml of water to remove the majority of bacteria from the worms. After the final removal of 
the supernatant, approximately 0.3 to 0.5 ml of worms were transferred to a 5 ml 
eppendorf tube and 3 ml of vehicle (0.97 or 1.94 mM HCl) or naltrexone HCl (10 or 20 
mM; dose selected from Cheong et al., 2015 [15]) was added to each tube.  These 
tubes were placed on a nutator for 30 min prior to EtOH preference testing.  Following 
vehicle or drug treatment, tubes were taken off nutator and worms were allowed to 
settle to the bottom of each tube for approximately 3 min. The supernatant was 
removed to a point were worms were diluted to a ratio of approximately 1 part worms to 
2 parts vehicle or drug solution. Then, 4 µl aliquots, containing approximately 40 to 80 
worms, were pipetted into the center of each well of a 6-well testing plate and excess 
liquid was removed from the worms using a Kimwipe.  Pictures of each well were taken 
30 min after placing worms on test plates (see Fig. 1 for schematic). 
2.4 EtOH Preference Testing Procedure 
In general, 4 μl of vehicle (water) and an EtOH solution were applied to the 
center of the 1.2 cm target zones of each well. These spotting solutions were allowed to 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 9 
absorb into agar for 30 min prior to testing. EtOH preference was tested on plates 
spotted with 0, 50, 70, or 95% (v/v) EtOH concentrations in one target zone and vehicle 
in the other. Vehicle (water) and drug solutions were prepared fresh, prior to each day 
of testing.  The use of the term “concentration dependent” is an operational definition 
defined by this procedure, in which different concentrations of EtOH were spotted in 4ul 
volumes to create EtOH target zones. When spotting the center of a target zone, these 
small volumes of EtOH are absorbed into the agar, diluting the EtOH and creating a 
concentration gradient from the center to the edge of the target zone. Thus, it is worth 
noting that worms were exposed to much lower concentrations of EtOH than what was 
used to spot the agar.  
2.5 Food Preference 
1 μl of water (control) or food (NA22 bacterial solution) was spotted to the two 
target zones of each well 30 min before testing. Images were taken at 30 min. In order 
to determine if naltrexone pretreatment produced nonselective effects on EtOH 
preference behavior, concentrations and volumes of food and benzaldehyde were 
selected to produce similar preference responses to those observed with EtOH.  
2.6 Benzaldehyde Preference  
2 μl of a 1%(v/v) benzaldehyde solution dissolved in 25%(v/v) EtOH was spotted 
in one target zone, while 25% EtOH was spotted in the opposite target zone, 30 min 
before testing. Images were taken at 30 min.  Typically, 95% EtOH is typically the 
diluent used for benzaldehyde. Since 95% EtOH was a preferred concentration of EtOH 
in our studies, we dissolved 1% benzaldehyde in 25% ethanol, since preliminary studies 
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determined that 25% EtOH by itself was not associated with EtOH preference in our 
assay (data not shown). 
2.7 Nonanone Aversion 
In order to determine if animals were capable of moving away from the EtOH 
target zones and were not rendered ataxic by EtOH, 2 μl of 10%(v/v) nonanone (an 
aversive compound) was spotted to the outer edge of the EtOH target zone of each well 
(i.e., between the edge of the EtOH target zone and the outer edge of the well) 
immediately after taking 30 min images for EtOH preference experiments. Therefore, 
images were taken immediately before and 10 min after placing nonanone into each 
well.  Pre- and post-nonanone PIs (as described below under EtOH preference testing) 
were calculated for each well in order to quantitate the change in preference from the 
EtOH target zone in response to nonanone. It should be noted that if animals display 
significant EtOH preference, then nonanone can be effective in reducing EtOH 
preference (i.e., moving them away from the EtOH target zone). In contrast, if animals 
do not display significant EtOH preference, then one may not be able to observe 
significant movement away from the EtOH target zone, since there is no significant 
EtOH preference to reduce (i.e., a floor effect).  We have observed this repeatedly 
throughout our testing (data not shown). 
2.8 Body Bend Assay 
The body bend assay used here was adapted from Hart, 2006 [21]. After 30 min 
pretreatment with vehicle (0.97 mM HCl) or naltrexone HCl (10 and 20 mM) (as 
described above in the naltrexone pretreatment section), 2 μl of worms diluted in a ratio 
of 1 part worms to 2 parts vehicle or drug were placed on a microscope slide on the 
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stage of a microscope (Bausch & Lomb ASZ45L3 45X). After selecting a single worm to 
track, the number of times the worm’s pharynx crossed this midline and extended to 
about a 45-90 degree arc over a 20-sec period was recorded. Only instances where the 
midline was completely crossed were counted.   Investigators were blind to the 
treatment group associated with a particular worm, in order to avoid biasing body bend 
data. 
2.9 Chronic EtOH Exposure  
 To create 300mM EtOH agar plates for chronic exposure, maintenance plates 
with bacteria were incubated at 37° C with lids off for 1.5 hrs.  After incubation, the 
weight of each plate was recorded and an appropriate volume of 95%(v/v) EtOH, based 
on the weight of the agar in the plate, was pipetted around the edges of the bacterial 
lawn. For example, if the volume of agar in a given plate was 10.0 ml, then 184.32 µl of 
95% EtOH was added to the surface of this agar plate to create a final EtOH 
concentration of 300mM.  The EtOH was allowed to absorb into the agar for at least 1 
hr, then plates were sealed with parafilm and stored at 4° C until ready to use.  Control 
plates were created using the same procedure, except that water was pipetted around 
the edges of the bacterial lawn instead of EtOH. Synchronized N2 wild-type worms in 
the L4 larval stage were transferred from EtOH-free maintenance plates to either 
300mM EtOH or control plates the day before testing and were allowed to develop to 
adults on the plates prior to experimental testing. This procedure was adapted from 
Davies et al., 2015 [22]. 
2.10 Imaging and Worm Counting 
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Worms were imaged by taking pictures with an Olympus 770sw digital camera 
positioned on top of a light box, which emitted light indirectly and underneath each 6-
well plate. Images were analyzed using ImageJ software to count the number of worms 
in the target zones of the test plates. Using ImageJ, the target zone was cropped from 
each photo and the color threshold of the image was adjusted. Specifically, threshold 
color was set to red, color space was set to RGB, and color threshold was adjusted so 
worms were highlighted in red. Particles were analyzed with a pixel size of 80 to infinity. 
The number of worms counted in each target zone was recorded and analyzed in 
Microsoft Excel. 
A chemotaxic preference index (PI) for each EtOH concentration was then 
calculated by dividing the number of worms in the EtOH target zone by the total sum of 
worms counted in both the EtOH and vehicle zones converted to a percentage.  Food 
and benzaldehyde preference were also determined using this same calculation.   
2.11 Determination of Internal EtOH Concentrations 
N2 gravid adult worms were used. As indicated in the Naltrexone Pretreatment 
and EtOH Preference Testing Procedure sections of the Methods, 4ul aliquots of worms 
were placed in the center of each well of a 6 well plate, previously spotted with 4ul of 
water in one target zone and 70% EtOH in the opposing target zone of each well. 
Worms were allowed to move in each well for 30 min. 6 well plates were placed on top 
of ice to immobilize worms to pick them from target zones. Individual worms were 
picked out of the water or 70% EtOH target zones using a platinum wire and placed in 
0.5 ml eppendorf tubes containing 40 µl of H20. The number of worms picked form the 
target zones was recorded for each sample and ranged from 74 to 120 worms per tube. 
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Tubes were stored at −80°C until analysis. Samples were thawed on ice and ground in 
the tube with a sonicator for 5 to 10 sec (Branson Sonifier 350 Cell Disruptor, Danbury, 
CT, USA). Sonicated worm homogenates were stored on ice prior to analysis.  
2.12 Gas Chromatography EtOH Concentration Analysis 
Internal worm EtOH concentrations were measured by gas chromatography (GC) with 
flame-ionization detection (FID) using a Shimadzu GC-2010 Plus gas chromatograph 
using a Phenomenex ZB-BAC2 column (30 m X 0.32 mm) and a HS-20 head space 
autosampler. Thirty µl samples of worm homogenates were added to a 10 ml glass GC 
head-space sampling vial containing 100 µl of saturated NaCl and sealed with a crimp-
cap septum seal.  Samples were heated to gaseous state and injected on to the gas 
chromatography system and detected with FID, as previously conducted [23]. The 
output was analyzed using LabSolutions chromatography analysis software and EtOH 
levels in samples were determined by comparison with a standard curve.  
2.13 Calculation of Internal EtOH Concentration  
The entire body volume of an N2 adult C. elegans was determined to be 5.5 nl/worm 
and since 80% of this volume has been determined to be water, the average internal 
body volume of an N2 adult C. elegans was estimated to be 4.4 nl/worm [24]. Therefore, 
we used the following calculations to determine the concentration of EtOH in a single 
worm from a sample containing 100 adult N2 worms in 40 µl of H20, for example: (1) 
4.4 nl/worm x 100 worms = 440 nl of worms (internal volume), and (2) 440 nl of worms 
(internal volume)/40,000 nl sample volume = 90.9(X) dilution for this sample. 
2.14 Statistical analyses 
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Data were analyzed using one, two, or three-way ANOVAs, followed by 
decomposition of factors and Bonferroni post hoc tests, as appropriate and previously 
conducted [9].  The statistical software used to perform these analyses was IBM© 
SPSS© Statics (version 25) for Mac.   
 
3. RESULTS 
3.1 Acute EtOH Preference in N2 strain 
 [Insert Figure 2 here] 
A two-way ANOVA found a main effect of pretreatment (vehicle vs. naltrexone) 
[F(2, 412) = 20.3, p < 0.001, ηp2 = .092], a main effect of EtOH concentration (0, 50, 70 
and 95% EtOH) [F(3, 412) = 5.0, p < 0.003, ηp2 = .036], and a significant interaction 
between pretreatment and EtOH concentration [F(6, 412) = 3.4, p < 0.004, ηp2 = .048] 
on EtOH preference (Fig. 2).  
For vehicle pretreated worms, a one-way ANOVA revealed a significant effect of 
EtOH concentration on EtOH preference [F(3, 254) = 11.9; p < 0.001], and Bonferroni 
post hoc tests revealed significant (p < 0.007) preference indices for 50, 70 and 95% 
EtOH compared to 0% EtOH. For 10 mM naltrexone pretreated worms, a one-way 
ANOVA found no effect of EtOH concentration on EtOH preference [F(3,68) = 1.3; ns]. 
For 20 mM naltrexone pretreated worms, a one-way ANOVA found a main effect of 
EtOH concentration on EtOH preference [F(3,90) = 3.4; p < 0.03].  For the 20 mM 
naltrexone treated group, Bonferroni post hoc tests found a significant (p < 0.02) 
increase in EtOH preference for 50% EtOH compared to 0%. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 15 
One-way ANOVAs examining differences between vehicle and naltrexone 
pretreatment groups for each EtOH concentration found no main effect of pretreatment 
on 0% EtOH preference [F(2,94) = 2.4, ns] or 50% EtOH [F(2,104) = 0.8, ns].  However, 
naltrexone pretreatment significantly decreased 70% EtOH preference compared to 
vehicle [F(2,107) = 24.2, p < 0.001] and Bonferroni post hoc tests found that 10 and 20 
mM naltrexone significantly (p < 0.001) decreased 70% EtOH preference compared to 
vehicle treatment. Naltrexone treatment significantly decreased 95% EtOH preference 
compared to vehicle [F(2,104) = 7.2, p < 0.002] and Bonferroni post hoc tests revealed 
that the 10 and 20 mM naltrexone significantly (p < 0.05) decreased 95% EtOH 
preference compared to vehicle treatment.  
The number of wells analyzed for the vehicle treated groups was 62 (0%), 63 
(50%), 66 (70%), and 64 (95%), for the 10 mM naltrexone treated group was 15 (0%), 
18 (50%), 18 (70%), and 17 (95%), and for the 20 mM naltrexone treated group was 18 
(0%), 24 (50%), 24 (70%), and 24 (95%). 
3.2 Acute EtOH Preference after Nonanone in the N2 Strain 
 A three-way repeated measures ANOVA on pre- vs post-nonanone EtOH 
preference found a main effect of nonanone on EtOH preference [F(1, 36) = 71.7; p < 
0.001, ηp2 = .666], with no significant effects of naltrexone treatment [F(1, 36) = 2.5; ns, 
ηp2 = .064] or EtOH concentration [F(1, 36) = 3.4; ns, ηp2 = .087].  In addition, no 
significant interactions were found on pre- vs post-nonanone EtOH preference.  
Bonferroni post hoc tests found a significant (p < 0.001) decrease in EtOH preference 
(collapsed across treatment and EtOH concentration) after nonanone presentation [pre- 
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(61.9 ± 3.3 %; n=40) vs post-nonanone (27.8 ± 4.5 %; n = 40) EtOH preference; data 
not shown].   
3.3 N2 Internal EtOH Concentrations 
The mean (± SEM) EtOH concentrations for worms picked from the 70% EtOH 
target zones were 115.5 (± 15.0) mg% (n = 6 samples), and from the water target zones 
were 2.5 (± 0.9) mg% (n = 4 samples).   
3.4 Control Experiments in the N2 Strain 
For vehicle, 10 and 20 mM naltrexone pretreatment, food preference was 79.6 ± 
4.7 (n = 24), 78.7 ± 2.9 (n = 18), and 71.8 ± 3.2 % (n = 21), respectively (Fig. 3A).  A 
one-way ANOVA found no main effect of naltrexone on food preference [F(2,62) = 1.2; 
ns, ηp2 = .039]. 
A one-way ANOVA found that naltrexone pretreatment (10 and 20 mM) had no 
significant effect on 1% (v/v) benzaldehyde preference [F(2,70) = 0.7; ns, ηp2 = .002].  
Mean benzaldehyde PI’s were 74.0 ± 4.9 % (n = 35), 71.4 ± 4.5 % (n = 24), and 72.1 ± 
8.6 % (n = 12), for the 0 (vehicle), 10 and 20mM naltrexone treatments, respectively 
(Fig. 3B). 
[Insert Figure 3 here] 
Exposure to 10 and 20 mM naltrexone for 30 min prior to testing had no 
significant effect on locomotor activity compared to vehicle exposure [F(2,46) = 0.71; ns, 
ηp2 = .031]. Specifically, the number of body bends in 20 sec for vehicle, 10 and 20 mM 
naltrexone treatments were 52 ± 3 (n = 19), 49 ± 3 (n = 16), and 46 ± 4 (n = 12), 
respectively (data not shown). 
3.5 Acute EtOH Preference in npr-17 KO and npr-17 Rescue Strains 
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A one-way ANOVA did not reveal a significant effect of EtOH concentration [F(3, 
178) = 0.5, ns, ηp2 = .009], on EtOH preference in npr-17 KO mutants (Fig. 4). The 
number of wells analyzed were 47 (0%), 36 (50%), 48 (70%), and 48 (95%). 
A two-way ANOVA found a main effect of pretreatment (vehicle vs. 10 mM 
naltrexone) [F(1,283) = 16.4, p < 0.001, ηp2 = .056], a main effect of EtOH concentration 
(water, 50, 70 and 95% EtOH) [F(3,283) = 7.0, p < 0.001, ηp2 = .070], and no interaction 
between pretreatment and EtOH concentration [F(3, 283) = 0.6, ns, ηp2 = .006] on EtOH 
preference in npr-17 rescue mutants (Fig. 5). The number of wells analyzed for the 
vehicle treated rescue mutant groups was 36 (0%), 36 (50%), 36 (70%), and 36 (95%), 
and for the 10 mM naltrexone treated group was 32 (0%), 36 (50%), 36 (70%), and 36 
(95%). 
 A three-way repeated measures ANOVA on pre- vs post-nonanone EtOH 
preference in npr-17 rescue mutants found a main effect of nonanone [F(1, 210) = 7.9; p 
< 0.007, ηp2 = .036], with no significant effects of 10 mM naltrexone treatment [F(1, 210) 
= 3.1; ns, ηp2 = .014] or EtOH concentration [F(2, 210) = 1.2; ns, ηp2 = .012].  In addition, 
a significant interaction was found between pre- vs post-nonanone EtOH preference 
and treatment F(1, 210) = 19.7; p < 0.001, ηp2 = .002].  Therefore, the data were 
collapsed across EtOH concentration and one-way ANOVAs were performed on pre- vs 
post-nonanone EtOH preference; these analyses revealed that vehicle-treated rescue 
mutants displayed significant decreases in EtOH preference after nonanone 
presentation [F(1, 107) = 22.0; p < 0.001], while naltrexone-treated rescue mutants did 
not exhibit significant changes in EtOH preference after nonanone presentation [F(1, 
107) = 1.7; ns].  Furthermore, pre-nonanone EtOH preference was significantly greater 
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for vehicle- versus naltrexone-treated rescue mutants [F(1, 215) = 18.9; p < 0.001], and 
post-nonanone EtOH preference was not significantly different between vehicle and 
naltrexone treated rescue mutants [F(1, 215) = 2.0; ns].  Fig. 6 shows pre- vs post-
nonanone EtOH preference data collapsed across EtOH concentrations (50, 70 and 
95%) for vehicle- and naltrexone-treated npr-17 rescue mutants. 
3.6 Food and Benzaldehyde Preference in N2, npr-17 KO and npr-17 Rescue 
Strains 
 Comparing NA22 food preference in vehicle treated N2, KO and rescue strains, a 
one-way ANOVA found a main effect of strain on food preference [F(2,71) = 4.4; p < 
0.02, ηp2 = .113].  Bonferroni post hoc tests found that N2 strain had significantly (p < 
0.02) lower food preference than npr-17 rescue mutants. Mean (± SEM) food 
preference indices were 79.6 ± 4.7 (n = 24), 87.3 ± 2.6 (n = 24), 93.7 ± 2.1% (n = 24) for 
N2, npr-17 KO and rescue strains, respectively (Table 1).   
Comparing 1% benzaldehyde preference in vehicle treated N2, KO and rescue strains, 
a one-way ANOVA found no effect of strain on benzaldehyde preference [F(2,78) = 1.2; 
ns, ηp2 = .032].  Mean (± SEM) benzaldehyde preference indices were 74.0 ± 4.8 (n = 
35), 80.0 ± 3.4 (n = 20), 82.7 ± 2.6% (n = 24) for N2, npr-17 KO and rescue strains, 
respectively (Table 1). 
3.6 Chronic EtOH Exposure and EtOH Preference in the N2 Strain 
 In chronic EtOH exposed wild-type worms, a two-way ANOVA found a main 
effect of EtOH concentration on EtOH preference [F(2,407 = 11.9; p < 0.001, ηp2 = 
.056].  However, naltrexone treatment had no effect on EtOH preference [F(2,407 = 1.8; 
ns, ηp2 = .009]. No significant interaction was observed between naltrexone treatment 
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and EtOH concentration [F(4,407) = 11.9; ns, ηp2 = .014]. Bonferroni post hoc tests 
found that significant (p < 0.001) increases in EtOH preference were observed for 50% 
and 70% EtOH compared to 0% EtOH (Fig. 7).   
It should be noted that the data from Figs. 7 and 8 were derived from the same 
animals.  Specifically, after animals were treated with vehicle or naltrexone to determine 
EtOH preference (Fig. 7), nonanone was applied to these same animals to determine 
their response to nonanone (Fig. 8).  Thus, animals were only treated with naltrexone 
on one occasion. A three-way repeated measures ANOVA in EtOH exposed worms 
found a significant main effect of nonanone [F(1,252) = 18.8; p < 0.001, ηp2 = .069] and 
naltrexone treatment on pre- versus post-nonanone EtOH preference [F(2,252) = 5.0; p 
< 0.008, ηp2 = .038].  No significant interactions were observed in the three-way 
ANOVA.  Bonferroni post hoc tests found that pre- versus post-nonanone EtOH 
preference, collapsed across EtOH concentrations (50 and 70%), was significantly (p < 
0.004) reduced by 20 mM naltrexone compared to vehicle treatment (Fig. 8). 
The number of wells analyzed for the vehicle treated groups was 45 (0%), 46 
(50%), and 48 (70%), for the 10 mM naltrexone treated group was 46 (0%), 43 (50%), 
and 44 (70%), and for the 20 mM naltrexone treated group was 48 (0%), 46 (50%), and 
42 (70%).  
 
4. Discussion 
 We have shown that C. elegans demonstrate movement toward, and 
concentration-dependent self-exposure to EtOH, which has been characterized as a 
“preference response” [14]. The recent discovery of opioid receptors in C. elegans 
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provided the impetus to test the hypothesis that C. elegans can be used as a 
medications screen to identify new treatments for AUDs. We tested the effects of 
naltrexone, an opioid antagonist and effective treatment for AUDs and other addictions, 
on EtOH preference in C. elegans. Naltrexone treatment blocked acute EtOH 
preference, but had no effect on motor activity or attraction to food or benzaldehyde, a 
volatile attractant. Opioid receptor knockout (KO) mutants did not display a significant 
preference response for EtOH. However, opioid receptor rescue mutants displayed 
EtOH preference behavior, which was attenuated by naltrexone, similar to findings 
observed in wild-type C. elegans. Chronic EtOH exposure in wild-type worms EtOH 
preference induced treatment resistance and aversion resistant behavior, as evidenced 
by the attenuated response to naltrexone and sustained self-exposure to EtOH in the 
presence of an aversive stimulus, nonanone. Together these data indicate that C. 
elegans have the potential to serve as a model system to identify compounds to treat 
AUDs and other addictive disorders. However, additional studies are needed to fully 
characterize the model and confirm that the phenomena observed thus far are 
consistent with efficacy of treatments for AUDs (i.e., verify predictive validity). Thus, 
future experiments will test compounds, previously shown to reduce EtOH drinking 
and/or seeking in vertebrate models, in the C. elegans EtOH preference test in acute 
and chronic models, to characterize the selectivity of the response. 
4.1 The EtOH Preference Assay 
A well-characterized and popular method to assess how C. elegans respond 
behaviorally to a chemical or substance is the simple chemotaxis assay [25, 26] that, in 
fact, is a type of voluntary self-exposure paradigm. Well described in previous studies 
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are findings of significant tissue EtOH concentrations after C. elegans are placed on 
agar plates that contain EtOH. The EtOH from the agar enters and accumulates in C. 
elegans to produce replicable behavioral responses, including locomotor inhibition [27] 
at internal tissue levels that produce similar responses in humans [13], and results in 
tolerance with extended periods of exposure [28]. The ingestion of substances by C. 
elegans in the absence of food is described as “drinking” behavior [29]. Such 
comprehensive studies under set conditions have led to the identification of genes that 
mediate the locomotor depressant effects of EtOH and tolerance; many of these genes 
are orthologs associated with AUDs in humans [27] (see [30] for review). 
The current findings build on these studies with some essential new methods to 
evaluate EtOH behavioral responses dependent on choice behavior as opposed to 
conditions of forced EtOH exposure. C. elegans show responses to various drugs of 
abuse, including stimulants and EtOH [9, 14, 31-33]. C. elegans have long been known 
to show chemotaxis toward EtOH [14]. Utilizing 6-well plates with 35mm testing areas 
(Fig. 1), we have shown clear, replicable concentration-dependent behavioral 
preference (PI significantly > 50% and significantly greater than control) responses for 
EtOH (Fig 2, vehicle). Importantly, we have shown that animals entering the target zone 
containing 70% EtOH quickly attain internal tissue EtOH concentrations of 25 mM (i.e., 
115 mg%). These levels are in agreement with previous work [13, 27], indicating that 
this is an EtOH self-exposure paradigm resulting in physiological internal EtOH 
concentrations, adding face validity to the model. Of note, the exogenous 
concentrations of all drugs used in the proposed studies are consistent with previous C. 
elegans work, and reflect the well-described barrier to entry associated with the cuticle 
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[15, 34, 35]. Our data indicates that in the acute model (i.e., EtOH naïve), addition of the 
aversive compound nonanone, near the target zone after the preference response has 
been established, causes the animals to immediately move away from the EtOH target 
zone, inducing a measurable aversive response. This indicates that EtOH is not simply 
functioning as a locomotor anesthetic or paralytic agent. From these data, we 
developed the hypothesis that C. elegans can be a viable model system to screen 
potential candidate drugs to treat AUDs.  
4.2 Findings with naltrexone 
Recently, C. elegans were found to have functional opioid-like receptors [15]. 
Thus, to determine the predictive validity of the model, we tested the effectiveness of 
naltrexone, one of the very few compounds shown consistently to reduce EtOH drinking 
behavior in animal models as well as humans [36]. In addition, naltrexone has been 
demonstrated to reduce opioid intake in animal models and humans [37], and has 
recently been shown to decrease cannabis self-administration and subjective effects in 
chronic cannabis users [38].  
In C. elegans, we found that exposure to naltrexone had no effect on locomotor 
activity (i.e., body bend assay), but significantly reduced the EtOH preference response 
(Fig. 2). This effect of naltrexone was not observed if food or benzaldehyde (Fig. 3) was 
used as the attractant in the place of EtOH. These data are consistent with rodent data 
showing that naltrexone can inhibit EtOH intake at doses that do not affect sucrose 
intake or body weight [39]. In most instances, little or no prior work has been published 
to determine if other treatments have effects on drug preference responses in C. 
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elegans. However, varenicline pre-exposure has been shown to reduce chemotaxis to 
nicotine in C. elegans [31, 33].  
4.3 Findings in Mutants 
The opioid receptor knockout mutant C. elegans, npr-17 KO, did not exhibit a 
preference for EtOH (Fig. 4). However, the opioid receptor rescue mutant C. elegans 
(npr-17 rescue) did display EtOH preference behavior, which was significantly reduced 
by naltrexone pretreatment (Fig. 5).  These findings in rescue mutants were similar to 
those observed in wild-type C. elegans (Fig. 2).  In agreement with the present findings, 
mu-opioid receptor knockout mice showed no evidence of EtOH self-administration in 
operant EtOH self-administration and two bottle-choice EtOH drinking paradigms [40]. 
Additional studies found decreased EtOH drinking in mu-opioid receptor knockout mice 
compared to wild-type mice [41-43]. In agreement with the aforementioned preclinical 
findings in C. elegans and mice, human studies support a role for polymorphisms in 
genes coding for MOR1, DOR1, KOR1, and other opioid receptors in clinical 
populations of alcoholics [44]. Overall, these findings suggest that opioid receptors play 
a critical role in behavior associated with EtOH self-exposure and self-administration, 
which is conserved across several different species, including worms, mice and 
humans. 
4.4 Chronic Exposure Model 
Chronic 300 mM EtOH exposure from the L4 larval stage to adulthood in N2 
worms: (1) resulted in similar EtOH preference behavior to that observed in untreated 
N2 worms (Fig. 7), (2) imparted resistance to the effect of naltrexone to reduce 
preference (Fig. 7), which is in agreement with the effects of chronic EtOH exposure in 
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rats [45]; and (3) reduced the effect of the aversive stimulus nonanone to move them 
away from EtOH (Fig. 8). This type of aversion-resistant EtOH self-exposure is 
consistent with models of compulsive EtOH self-administration in rats [46]. Interestingly, 
naltrexone treatment enabled the normal aversive response to nonanone from both the 
50 and 70% EtOH target zones (Fig. 8).   
With regard to acute versus chronic EtOH exposure models, some of the most 
promising therapeutics compounds for the treatment of AUDs do not modify acute EtOH 
reward and/or reinforcement, but instead target neuroadaptations produced after 
chronic EtOH exposure that regulate maladaptive behavior in mammalian models [47, 
48], and similar distinctions may be observed in C. elegans. It is, therefore, important to 
examine effects after chronic EtOH exposure, previously shown to enhance EtOH 
preference in C. elegans [14]. The EtOH exposure model utilized here can differentiate 
the effects of potential treatments on acute vs. chronic effects of EtOH and is able to 
identify compounds that may only show significant effects in models of chronic 
exposure. Additionally, the attenuated response of naltrexone to reduce EtOH 
preference in chronic vs. acute exposure for some inhibitors might model treatment 
resistance in EtOH-adapted subjects and/or have differential effects on compulsive self-
exposure as observed with naltrexone in the current findings, consistent with reports in 
rats [45]. 
C. elegans has a simple nervous system that lacks the complex neurocircuitry of 
mammals involved in addiction [3]. However, C. elegans phenotypes are highly 
conserved functionally and clear parallels are observed in neurobiology, pharmacology, 
and molecular systems compared to vertebrates. The similarities in responses to 
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substances of abuse between C. elegans and mammals suggests that the behavioral 
responses to drugs of abuse may depend more on functional similarities rather than 
complexities in the neuroanatomy. This seems particularly relevant in terms of how 
substances of abuse affect systems that mediate survival in the active search for food. 
However, it is possible that differences in neurotransmitter receptor systems and 
molecular pharmacology in C. elegans could also be advantageous in terms of 
providing a unique perspective concerning how some classes of potential treatments 
affect the appetitive properties of substances of abuse. For example, one potential 
treatment for AUDs that has been identified is topiramate [49]. Several cellular targets 
have been proposed to be involved in the therapeutic activity of topiramate and there 
are several possible molecular mechanisms by which topiramate may reduce EtOH 
reinforced behaviors. One possible mechanism could be through topiramate’s ability to 
blockade voltage-sensitive sodium channels [49], which are absent in C. elegans [50]. 
So, if topiramate were found to be ineffective in modifying EtOH preference behavior in 
C. elegans, this would suggest that sodium channels may have a role in reducing the 
appetitive properties of EtOH in vertebrates. Thus, cross-species findings could be 
assessed with respect to molecular homology of the mechanisms proposed to be 
mediating the appetitive or reinforcing properties of EtOH. Overall, these types of 
studies will help to characterize the molecular and pharmacological foundations of the 
effects of these compounds, regardless of whether the findings are consistent with the 
anticipated results. 
In summary, our data indicate that C. elegans exhibit a concentration-dependent 
attraction to EtOH, which previous work shows results in self-exposure and elevations 
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of internal concentrations of EtOH to levels associated with intoxication in humans. As 
observed in the EtOH naïve worms, the EtOH preference response in worms chronically 
exposed to EtOH was not due to an anesthetic or paralytic effect. In addition, we found 
that naltrexone could selectively reduce EtOH self-exposure in this paradigm. Moreover, 
chronic EtOH exposure induces treatment resistance and aversion resistant behavior as 
evidenced by naltrexone’s inability to modify EtOH preference and sustained self-
exposure to EtOH in the presence of the aversive stimulus nonanone. These data are 
consistent with the efficacy of naltrexone in vertebrate animal models and humans, 
providing face and predictive validity for the model. 
In the present studies, we establish and provide support for a high-throughput C. 
elegans behavioral medications screening model to enable fast and accurate generation 
of data. Although naltrexone has effects on the acute and rewarding properties of EtOH, 
as well as the relapse-inducing effects of chronic EtOH [17], some promising new 
agents only show efficacy in chronic models [2, 47]. Therefore, future studies will test 
compounds in both acute and chronic exposure models to compare effects with those 
observed in vertebrate models. The further development and application of this model 
may provide the field with a new and powerful tool to discover novel targets and 
treatments for AUDs.  
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Fig. 1. Drug Preference Testing Paradigm. Worms were exposed to either vehicle 
(0.97 and 1.94 mM HCl) or naltrexone HCl (10 and 20 mM) in a centrifuge tube for 30 
min prior to the ethanol (EtOH) preference testing. Animals were then pipetted into the 
center of each well of a 6-well agar test plate containing two target zones; one spotted 
with EtOH and the other with vehicle.  Images were taken 30 min after plating worms to 
determine an EtOH preference index for each well. 
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Figure 2.  Pretreatment with 10 and 20 mM naltrexone decreased EtOH preference 
in N2 C. elegans. Vehicle pretreated worms displayed significant (p < 0.05) preference 
indices for 50, 70 and 95% EtOH compared to water, as indicated by *.  10 mM 
naltrexone significantly (p < 0.05) decreased 70% and 95% EtOH preference compared 
to vehicle pretreatment, as indicated by +.  Similarly, 20 mM naltrexone significantly (p < 
0.05) decreased 70% and 95% EtOH preference compared to vehicle pretreatment, as 
indicated by #.  The number of wells analyzed for the vehicle treated groups was 62 
(0%), 63 (50%), 66 (70%), and 64 (95%), for the 10 mM naltrexone treated group was 
15 (0%), 18 (50%), 18 (70%), and 17 (95%), and for the 20 mM naltrexone treated 
group was 18 (0%), 24 (50%), 24 (70%), and 24 (95%). 
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Figure 3. Pretreatment with 10 or 20 mM naltrexone does not alter food (NA22) or 
benzaldehyde preference in N2 C. elegans.  Worms were pretreated with vehicle, 10, 
or 20 mM naltrexone for 30 min and subsequently tested for food or benzaldehyde 
preference.  Panel A: 1 µl of water or food was spotted to the two target zones of each 
well. Naltrexone had no significant effect on food preference compared to vehicle 
pretreatment. The number of wells for the vehicle, 10 and 20 mM naltrexone groups 
was 24, 18 and 21, respectively.  Panel B: 2 µl of a 1% (v/v) benzaldehyde solution 
dissolved in 25% (v/v) EtOH was spotted in one target zone, while 25% EtOH was 
spotted in the opposite target zone. No statistically significant differences were found 
between treatment groups. The number of wells analyzed for the vehicle, 10 and 20 mM 
naltrexone conditions were 35, 24 and 12, respectively. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 34 
 
Figure 4. EtOH preference in npr-17 KO mutant C. elegans. A one-way ANOVA did 
not reveal a main effect of EtOH concentration on EtOH preference [F(3, 178) = 0.5; ns] 
npr-17 KO mutants.  The number of wells analyzed for npr-17 KO mutants were 47 
(0%), 36 (50%), 48 (70%), and 48 (95%). 
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Figure 5. EtOH preference in npr-17 Rescue mutant C. elegans.  A two-way ANOVA 
found a main effect of pretreatment (vehicle vs. 10 mM naltrexone) [F(1,283) = 16.4, p < 
0.001], a main effect of EtOH concentration (water, 50, 70 and 95% EtOH) [F(3,283) = 
7.0, p < 0.001], and no interaction between pretreatment and EtOH concentration [F(3, 
283) = 0.6, ns] on EtOH preference in npr-17 rescue mutants (Fig. 5). * indicates a 
significant effect of EtOH concentration, while + indicates that naltrexone significantly 
decreased EtOH preference compared to the vehicle condition. The number of wells 
analyzed for the vehicle treated rescue mutant groups was 36 (0%), 36 (50%), 36 
(70%), and 36 (95%), and for the 10 mM naltrexone treated group was 32 (0%), 36 
(50%), 36 (70%), and 36 (95%). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 36 
 
Figure 6. Pre- vs post-nonanone EtOH preference data collapsed across EtOH 
concentrations (50, 70 and 95%) for vehicle- and naltrexone-treated npr-17 rescue 
mutants. A three-way repeated measures ANOVA on pre- vs post-nonanone EtOH 
preference in npr-17 rescue mutants found a main effect of nonanone [F(1, 210) = 7.9; p 
< 0.007], with no significant effects of 10 mM naltrexone treatment [F(1, 210) = 3.1; ns] 
or EtOH concentration [F(2, 210) = 1.2; ns].  A significant interaction was also found 
between pre- vs post-nonanone EtOH preference and treatment F(1, 210) = 19.7; p < 
0.001].  Therefore, the data was collapsed across EtOH concentration and a one-way 
ANOVAs was performed on pre- vs post-nonanone EtOH preference. Vehicle-treated 
rescue mutants displayed significant decreases in EtOH preference after nonanone 
presentation [F(1, 107) = 22.0; p < 0.001] as indicated by *, while naltrexone-treated 
rescue mutants did not exhibit significant changes in EtOH preference after nonanone 
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presentation [F(1, 107) = 1.7; ns].  Furthermore, pre-nonanone EtOH preference was 
significantly greater for vehicle- versus naltrexone-treated rescue mutants [F(1, 215) = 
18.9; p < 0.001] as indicated by **, and post-nonanone EtOH preference was not 
significantly different between vehicle and naltrexone treated rescue mutants [F(1, 215) 
= 2.0; ns].   
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Figure 7. Effects of Chronic EtOH exposure and Naltrexone on EtOH preference in 
N2 C. elegans. In chronic EtOH exposed wild-type worms, a two-way ANOVA found a 
main effect of EtOH concentration on EtOH preference [F(2,407 = 11.9; p < 0.001) ].  
However, 10 and 20 mM naltrexone treatments had no effect on EtOH preference 
[F(2,407 = 1.8; ns)].  Bonferroni post hoc tests found that significant (p < 0.001) 
increases in EtOH preference were observed for 50% and 70% EtOH compared to 0% 
EtOH as indicated by *.  The number of wells analyzed for the vehicle treated groups 
was 45 (0%), 46 (50%), and 48 (70%), for the 10 mM naltrexone treated group was 46 
(0%), 43 (50%), and 44 (70%), and for the 20 mM naltrexone treated group was 48 
(0%), 46 (50%), and 42 (70%). 
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Figure 8. Effects of Chronic EtOH exposure and Naltrexone on response to 
nonanone in N2 C. elegans. A three-way repeated measures ANOVA in EtOH 
exposed worms found a significant main effect of nonanone [F(1,252 = 18.8; p < 0.001)] 
and naltrexone treatment on pre- versus post-nonanone EtOH preference [F(2,252 = 
5.0; p < 0.008)].  Since there was no significant effect of EtOH concentration, the data 
was collapsed across the 50 and 70% EtOH concentrations.  Bonferroni post hoc tests 
found that pre- versus post-nonanone EtOH preference was significantly (p < 0.004) 
reduced by 20 mM naltrexone compared to vehicle treatment, as indicated by *. 
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Table 1. Mean (± SEM) Food and Benzaldehyde Preference in N2, npr-17 KO and 
Rescue Mutants 
Strain Food  Benzaldehyde  
   N2 (wild-type)           *79.6 ± 4.7 % (n = 24)  74.0 ± 4.8 % (n = 35) 
npr-17 KO         87.3 ± 2.6 % (n = 24)  80.0 ± 3.4 % (n = 20) 
npr-17 Rescue             93.7 ± 2.1 % (n = 24)  82.7 ± 2.6 % (n = 24) 
 
*Post hoc tests found that N2 food preference was significant higher in npr-17 rescue 
mutants compared to N2 worms.  No other significant differences were observed in N2, 
npr-17 KO, and npr-17 rescue mutants, in terms of food or benzaldehyde preference.   
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